How do I know if I am a candidate for CAR-T therapy?

CAR-T therapy is a groundbreaking treatment primarily designed for patients with specific types of hematologic malignancies, including multiple myeloma, B-cell lymphomas, and leukemia. The suitability for CAR-T therapy is typically determined by various factors, such as the type and stage of the disease, the patient's overall health, and prior responses to other treatments. Our medical team will provide a comprehensive assessment free of charge to ascertain whether CAR-T therapy is suitable for you. This assessment includes a review of your medical history, diagnostic results, and an online consultation with top experts in China.

Pic

What questions can I pose to the CAR-T treatment team?

When contemplating CAR-T therapy, effective communication with the treatment team is crucial. Here are some questions you may wish to ask:

1. Am I a suitable candidate for CAR-T therapy?

Understanding the specific criteria that make you an eligible candidate.

2. What are the potential risks and side effects?

Gaining insights into expected adverse reactions and how they will be managed.

3. How is CAR-T therapy conducted?

Understanding the treatment process, including cell collection, genetic engineering, and infusion.

4. What is the expected timeline for the treatment?

Obtaining an overview of the duration of each phase, from preparation to expected recovery.

5. What post-treatment care is included?

Understanding the monitoring and support provided by the medical team after treatment.

6. What is the success rate of CAR-T therapy for my specific condition?

Discussing the likelihood of treatment success and potential outcomes.

7. What is the total expected cost of the entire treatment in China?

Understanding and preparing adequate funding for the treatment.

Our professional CAR-T treatment team will maintain open and clear communication with you, crucial for making informed decisions about your health. Additionally, our VIP services ensure that any questions or situations that arise during your treatment in China are addressed promptly. For inquiries, please click below:

Request a Consultation Now for Car-t Programs for Multiple Myeloma

*Required
Upload case photos for expert advice

Maximum 6 images,3Mb each picture limited
Fucaso® (Equecabtagene Autoleucel Injection)

-- The World's First Approved Fully Human CAR-T Therapy

Breakthrough fully human CAR structure
  • Full epitope of light and heavy chains binds tightly to BCMA
  • Fast dissociation, low exhaustion
  • Low immunogenicity
Durable persistence
  • Median duration of persistence time 419 days
  • 12-month sustained MRD negativity rate 81.7%
  • 12-month PFS rate 85.5%
Strong efficacy
  • ORR 98.9%
  • ≥CR rate 82.4%
  • MRD negativity rate 97.8%
Returning to life upon single-dose treatment
Excellent safety
  • No ≥ Grade 3 ICANS
  • Incidence of ≥ Grade 3
  • No movement/cognitive disorder observed No Parkinson's disease found